Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising?

Malcolm G P Page; Karen Bush

doi:10.1016/j.coph.2014.09.008

Discovery and development of new antibacterial agents targeting Gram-negative bacteria in the era of pandrug resistance: is the future promising?

Curr Opin Pharmacol. 2014 Oct:18:91-7. doi: 10.1016/j.coph.2014.09.008. Epub 2014 Sep 29.

Authors

Malcolm G P Page¹, Karen Bush²

Affiliations

¹ Basilea Pharmaceutica International Ltd, Basel, Switzerland.
² Indiana University, Simon Hall, 212 S. Hawthorne Drive, Bloomington, IN, USA. Electronic address: karbush@indiana.edu.

PMID: 25277839
DOI: 10.1016/j.coph.2014.09.008

Abstract

Multidrug-resistant Gram-negative bacteria continue to pose a threat, with many infections caused by these pathogens being virtually untreatable. A number of new antibacterial agents are in late stage clinical development to treat these infections. Drugs in known classes such as new quinolones, aminoglycosides, tetracyclines, and β-lactams have been designed to evade many of the known resistance mechanisms, whereas newer drug classes include novel β-lactamase inhibitors in combination with new or approved β-lactams, and a peptidomimetic that have entered full clinical development. The establishment of public-private partnerships and an increase in pharmaceutical interest in antibacterial R&D are encouraging signs for the future.

Publication types

Review

MeSH terms

Anti-Bacterial Agents / pharmacology*
Drug Discovery
Drug Resistance, Multiple, Bacterial / drug effects*
Drugs, Investigational / pharmacology*
Gram-Negative Bacteria / drug effects*
Humans
Public-Private Sector Partnerships

Substances

Anti-Bacterial Agents
Drugs, Investigational